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Abstract | Puberty suppression using gonadotropin-releasing-hormone analogues (GnRHa) has 
become increasingly accepted as an intervention during the early stages of puberty (Tanner stage 2–
3) in individuals with clear signs of childhood onset gender dysphoria. However, lowering the age 
threshold for using medical intervention for children with gender dysphoria is still a matter of 
contention, and is more controversial than treating the condition in adolescents and adults, as 
children with gender dysphoria are more likely to express an unstable pattern of gender variance. 
Furthermore, concerns have been expressed regarding the risks of puberty suppression, which are 
poorly understood, and the child’s ability to make decisions and provide informed consent. 
However, even if the limited data available mean that it is not possible to make a conclusive 
treatment recommendation, some safety criteria for puberty suppression can be identified and 
applied. 
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We may suppose that there have always been people who have wished to cross the gender 
line in terms of attire, presentation, comfort, behaviour, and relationships. However, only in the past 
few decades has gender nonconformity consistently been shown to be associated with clinical 
distress or impairment in important areas of functioning1, requiring clinical attention in some 
individuals. The work of Harry Benjamin and the World Professional Association for Transgender 
Health (WPATH), who in 1953 designated ‘transsexualism’ as an autonomous clinical entity2, has 
eventually led to a recommended procedure for managing distress arising from the incongruity of 
assigned sex at birth and internal experience of gender. The main goals of this approach are 
summarized in the WPATH Standards of Care3, which define available treatment options in order to 
ensure and promote the highest standards of health care for children, adolescents, and adult 
individuals seeking gender transitioning. This treatment programme includes hormonal and surgical 
interventions, which are considered after a careful diagnostic phase and only after real-life 
experience in the desired gender role. The WPATH Standards of Care also encourages evaluation 
and recommendations by mental health professionals (including assessment, counselling, and 
psychotherapy), and hormonal and surgical treatments. Moreover, this approach actively promotes 
the individual’s well-being, destigmatizing gender variance, and supports the creation of a safe 
environment in order for children and adolescents with gender dysphoria to express themselves, and 
encourages parents to support their gender-variant children4. 
In 1980, the American Psychiatric Association (APA) first included the condition — known 
then as ‘transsexualism/gender identity disorder’—  in the Diagnostic and Statistical Manual 
(DSM)5, acknowledging the possibility that it could exist in children or adolescents. The inclusion 
of gender variance in a psychiatric manual was seen by many to pathologize nonconforming gender 
identity and expression, and to reinforce gender stereotypes. However, substantial changes have 
been made to the diagnostic criteria over the subsequent 30 years, in an attempt to better define the 
condition and to find a balance between the competing issues of stigma and access to care6-9. In 
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2013, APA renamed the condition ‘gender dysphoria’ in order to better characterize gender-related 
discomfort8. 
The core feature of gender dysphoria is a marked incongruence between one’s experienced 
and/or expressed gender and assigned gender (usually assigned at birth, and referred to as natal 
gender), of at least 6 months duration. However, according to DSM-5, different diagnostic criteria 
apply to adults and adolescents on one hand, and children on the other. Whereas only two gender-
variant behavioural manifestations are required to diagnose gender dysphoria in adults and 
adolescents (Box 1), six criteria are required to reach the diagnosis in children, one of which must 
be the clinical evidence of the child’s strong desire to be of the non-natal gender or insistence of 
being the non-natal gender (Box 2). Furthermore, clinically significant psychosocial distress or 
impairment is needed in order to diagnose gender dysphoria, regardless of the age of the 
individual8.  
 
[H1]Development of gender identity  
Gender identity serves as a social identity at an individual as well as a collective level. Its 
development begins at an early stage of human life; research has shown that around the age of 
3 years, children show a basic sense of self as male or female10, owing to their inner experience of 
belonging to one gender11, 12. Furthermore, at 6–7 years of age a child realizes that one’s gender is 
likely to remain constant13-15. Some research suggests that a developmental lag exists in gender 
constancy acquisition in children with gender-variant behaviour16. Achieving gender constancy 
represents a cognitive-developmental milestone in gender identity development17-19 and is due to the 
understanding that being male or female is a biological characteristic that cannot be changed by 
altering superficial attributes, such as hairstyle or clothing11. The ability to classify oneself and 
others as male or female also has strong affective components20. 
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Epidemiological studies on the incidence and prevalence of gender-variant behaviour and 
gender dysphoria  are usually based on patients presenting at gender identity clinics, and efforts to 
achieve realistic estimates are fraught with difficulties21-24. The incidence of gender dysphoria is 
regarded as remaining constant, whereas the prevalence of the condition has shown great variation 
between the first and the most recent studies, diverging among countries and even between different 
epochs within the same country. Prevalence estimates are strongly affected by recruitment 
strategies, diagnostic criteria, treatment availability, and eligibility23, 24. A 2015 meta-analysis of 21 
studies concluded that the prevalence of gender dysphoria  is 1 in 14,705 in adult males and 1 in 
38,461 in adult females25. Moreover, an interesting study has indicated that the numbers of referrals 
to specialized clinics for gender dysphoria have increased between 2006 and 2013 together with a 
corresponding shift in the sex ratio, from one favouring natal males to one favouring natal females 
26. Although gender-variant behaviour has been shown to be frequent in children, ranging from 2–
23% for natal males and 4–39% for natal females27, 28, numbers are definitely smaller when 
considering gender-variant adolescents reporting discontent with their assigned gender and/or 
seeking hormone treatment or some form of surgery (0.6% of the natal males and 0.2% of the natal 
females)29. These findings seem to suggest that there isn’t a direct relationship between the 
experience of gender-variant behaviour, the dislike of one’s natal sex characteristics, and the desire 
to undergo sex reassignment procedures, providing support for a dimensional approach to gender 
dysphoria29. In contrast to studies of gender-variant behaviour, studies attempting to investigate the 
prevalence of gender dysphoria according to the DSM-5 diagnostic criteria8 report even lower rates 
in adults, ranging from 0.005–0.014% for natal males and 0.002–0.003% for natal females8. 
Very little is known about the trajectory of the condition in gender-variant children who meet the 
criteria for a gender dysphoria diagnosis as an adult. The percentage of children initially diagnosed 
with gender dysphoria who display persistence of the condition ranges from 12–27%30-32, indicating 
that the majority of children meeting gender dysphoria  criteria do not have persistence of the 
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condition by the time they have entered puberty. This finding could be partially explained by the 
internalized social pressure to conform33, although this hypothesis is still untested34. However, the 
possibility of an original misdiagnosis (false positive) should also be considered33, 34. Regardless of 
these limitations, it is thought that an increased number and intensity of gender-variant phenomena 
in childhood, gender dysphoria persistence in adolescence, and cognitive dimensions of gender 
identity nonconformity (rather than emotional dimensions) could predict an increased likelihood of 
gender dysphoria persistence into adulthood35-37. 
 
[H1]Clinical evidence in children 
Gender variance is conceptualized as a spectrum of gender identity-related phenomena rather than a 
homogeneous phenomenon24. In an attempt to define possible gender dysphoria-related 
characteristics and predictors of outcome, two subtypes of gender dysphoria have been suggested, 
an early-onset (prepubertal) group and a late-onset (peripubertal or postpubertal) group. These 
groups have been summarized in the DSM-58. Some researchers and clinicians have suggested that 
early-onset gender-dysphoric individuals might present with more constant forms of gender 
dysphoria or gender variance from childhood onwards than the late-onset group and identify with 
homosexual sexual orientation more frequently, and could benefit from early medical intervention24, 
38. Children in the early-onset group can experience substantial distress at the physical changes of 
puberty and gender dysphoria can even become more intense at this time24. Instead, late-onset 
gender dysphoria individuals could present with a more fluctuating gender-variant behaviour, not 
necessarily needing gender reassignment24.  
Regardless of the course of the condition, it is not possible to safely differentiate between 
children who will show persistence of gender-variant behaviour in adulthood from those who will 
instead show desistence and conform to their natal gender39. The optimal approach to treating 
prepubertal children with gender dysphoria is, therefore, still a matter of contention and is more 
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controversial than treating the condition in adolescents and adults, who are more likely to express a 
stable pattern of gender variance39. Furthermore, research into treatment outcomes in children with 
gender dysphoria is still at an early stage, with a few studies which have investigated the effect of 
puberty suppression on psychosocial functioning and mental wellbeing40-42. To date, only one long-
term follow-up study has indicated that a treatment protocol including puberty suppression leads to 
a psychosocial functioning in late adolescence that is comparable to non-gender dysphoric peers41. 
Moreover, randomized controlled trials to study treatment outcomes in children with  gender 
dysphoria are still needed43. According to the WPATH Standards of Care, adolescents should be 
considered eligible for puberty suppression based on five criteria: evidence of  gender dysphoria 
from early childhood onwards, an increase in the intensity of gender dysphoria after the first 
pubertal changes,  no signs of psychiatric comorbidity, provision of adequate psychological and 
social support during the treatment, and demonstration of knowledge and understanding of the 
effects of puberty suppression by the patient3.  
 
[H1]Approaches to treatment in childhood 
 
The report from the APA Task Force on treatment of gender dysphoria39 has highlighted the 
challenging issue of capacity in children when considering treatment options; from a developmental 
point of view, children are regarded as not having the ability to make decisions and they lack the 
legal ability to provide informed consent. Treatment for gender dysphoria — especially puberty 
suppression — is particularly controversial and no agreement has been reached among clinicians 
and researchers on a specific care pathway for gender dysphoria in childhood. As a consequence, 
treatment options need to be discussed in a wider context, in which caregivers have the 
responsibility of making treatment decisions on the patient’s behalf, with potentially lifelong 
consequences. 
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Experts and health-care providers agree that psychotherapy represents a fundamental part of 
treatment for gender dysphoria in childhood, in order to promote the individual’s self-confidence 
and well-being. One study has indicated that psychological support after diagnosis has an effect on 
its own in improving the psychosocial functioning of gender dysphoric adolescents40. However, 
clinicians disagree on what they consider the main goal of offering psychological support to young 
people with gender dysphoria. Three different approaches can be identified, which use divergent 
clinical paradigms to address the issue of gender dysphoria in children. The first approach relies on 
the concept that minimization of gender-variant behaviour in children should be actively promoted 
in order to reduce the likelihood of gender dysphoria persistence in adulthood43. Personal, 
philosophical, or ethical considerations regarding the inappropriateness of allowing gender-variant 
behaviour in children, as well as practical issues, such as the high cost of gonadotrophin-releasing-
hormone antagonists (GnRHa) for puberty suppression and other sexual reassignment procedures, 
lead some clinicians to consider persistence of gender dysphoria into adulthood undesirable43-45. 
Some clinicians criticize the medical treatment of young individuals with gender dysphoria, stating 
that a diagnosis of gender dysphoria cannot be made in preadolescents, as their gender identity is 
still fluctuating and developing33, 34. Other professionals fear that puberty suppression could 
crystallize gender dysphoria, inhibiting the development of a gender identity correspondent to the 
natal sex46. Most importantly, this approach is based on the evidence is that only a minority of those 
with untreated childhood gender dysphoria will identify as transsexual or transgender in adulthood, 
while the majority will become comfortable with their natal gender over time33, 34, 44. Furthermore, 
concerns have been raised regarding the risks of puberty suppression — including effects on brain 
development and other physical issues, such as bone density alteration — which are still not fully 
understood39, 47. To date, only one study has assessed the effect of GnRHa on cognition in gender 
dysphoria, reporting no evidence for a deleterious effect of puberty suppression on brain activity 
and related executive functioning48. Also, bone mineral density has been recently studied for the 
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first time in a cohort of gender dysphoria individuals receiving puberty suppression, suggesting that 
these individuals may face loss of bone mass if cross-sex hormonal treatment is postponed beyond 
the age of 16 years49.  
A second approach considers it crucial not to interfere with the child’s development. 
Compared with the first approach, this ethos does not consider a therapeutic target to lessen gender-
variant behaviour and instead promotes neutrality with respect to the patients’ gender identity 
outcome. Like the first approach, the basis of this strategy is the absence of clear-cut predictors of 
gender dysphoria persistence in adulthood and the evidence that a substantial percentage of gender-
variant behaviour in childhood will not culminate in adult gender dysphoria30, 44. The goal of this 
outcome is to allow the developmental trajectory of gender identity to unfold without pursuing or 
encouraging a specific outcome50-52. It does not exclude active support of the child’s social 
integration and well-being, in order to minimize social risks and stressors, and self-recognition of 
gender variance can be encouraged, and behavioural, cognitive and emotional coping strategies can 
be promoted50, 53, 54.  
The third approach is based on the concept that abstaining from medical intervention could 
do even more harm to the child. In this framework, health-care professionals and carers should 
actively support the child’s affirmation as a member of the desired gender. As a consequence, the 
option of endocrine treatment to suspend and/or suppress puberty should be considered, in order to 
facilitate a gradual and more efficient gender transition. The rationale for supporting transition 
before puberty is the belief that some children will still express a stable pattern of gender variance 
into adulthood. Enabling them to make important age-appropriate developmental transitions, 
puberty suppression (and subsequent sex reassignment procedures, such as cross-sex hormonal 
treatment and gender reassignment surgery) would contribute to a satisfactory objective and 
subjective well-being in young adulthood41, and a more favourable surgical outcome55. 
Accordingly, undergoing the pubertal development of their biological sex could increase the 
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distress already associated with the condition, with serious risks for the individual’s psychological 
well-being56. As studies have indicated that cross-sex hormonal treatment improves well-being in 
adults with gender dysphoria57-59, research has begun to focus on the effects of puberty suppression 
on quality of life in prepubertal and adolescent individuals with gender dysphoria, indicating that 
this early intervention could improve their psychosocial functioning and well-being40-42. However, 
the available evidence is currently too limited to draw definite conclusions. A team from the 
Netherlands has been an influential leader in promoting a protocol — the so-called Dutch protocol 
— which recommends treatment of minors with gender dysphoria after an extensive psychological 
and psychiatric evaluation, with puberty suppression at the age of 12 years and after the first stages 
of puberty (Tanner stage 2–3) have been reached55, 60 (Box 3). This team have also provided 
evidence that no young individual eligible for GnRHa has dropped out of treatment or shown regret 
during puberty suppression61, 62. The cornerstone of this approach is the evidence that, although 
puberty suppression seems to reduce the gender dysphoria-related distress40-42, and seems to be a 
relatively safe and reversible procedure46, 60, not treating gender dysphoria in childhood cannot be 
considered a neutral option, as delaying treatment until late adolescence or adulthood might lead to 
the development of psychiatric concerns, social isolation, and impaired functioning46. However, the 
Dutch team does consider the possibility of delaying eligibility for puberty suppression in patients 
with concomitant psychiatric or psychosocial difficulties requiring intervention. 
 
[H1]Balancing observation and intervention 
Although medical treatment and health risks63 in gender dysphoric adults are well defined 
and have been the object of more extended research in clinical settings57-59, the treatment strategy 
for young persons has received little attention in clinical research settings and is still debated56. 
According to the Task Force for gender dysphoria, specific health-care pathways for young 
individuals with gender dysphoria have not been properly investigated owing to the absence of 
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randomized or adequately controlled longitudinal studies39. As a consequence, conclusive treatment 
recommendations for puberty suppression cannot be made. Clinicians disagree about the 
appropriateness of puberty suppression because of their professional background and religious or 
ethical convictions, and the individual, their carers, or the health-care professionals could hold 
different views, making even more difficult to reach agreed solutions.  
In their Task Force treatment recommendation, Byne and colleagues39 suggest that any 
treatment decision in children presenting with gender-variant behaviour should be made only after 
extensive evaluation of the patient’s gender-related issues, including identity, role, and behaviour, 
after addressing any potential concerns of the caregivers or difficulties in their relationship with the 
patient, and after providing psychoeducation, counselling, and informed consent to any treatment 
option and outcome from caregivers, in order to support their decision. Treatment should only be 
initiated after disclosing the limitations of the available data on both outcome and risks of the 
treatment, having provided information to the child that can be understood, and only in the context 
of the patient’s mental health and psychosocial environment, including family, school, and larger 
community.  
In an attempt to balance the benefits and risks of puberty suppression, and in light of all the 
available information and knowledge, our opinion is that the enlightened decision would be to allow 
puberty suppression when the adverse outcomes of a lack of or delayed intervention outweigh the 
adverse outcomes of early intervention in terms of long-term risks for the child. In other words, if 
allowing puberty to progress seems likely to harm the child in terms of psychosocial and mental 
well-being, puberty should be suspended. 
 
[H1]A multidisciplinary approach  
[H2] Psychological support  
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The treatment protocol for individuals with gender dysphoria should include a number of 
different components in order to promote the most satisfactory outcome64, 65. The two main goals of 
gender dysphoria treatment are to support the patient’s transition, aligning the phenotype with the 
experienced and/or expressed gender identity, and to support their psychosocial well-being. These 
outcomes are interlinked and are better achieved using a multidisciplinary approach, involving both 
physical and nonphysical interventions41.  
Although medical and surgical interventions are fundamental to obtaining a physical 
appearance in line with the desired gender, psychotherapy and psychological support are considered 
of great importance in helping the individual to identify and work through the factors that will 
contribute to his or her decision to undergo cross-sex medical intervention. Psychological and 
psychotherapeutic settings give patients the opportunity to discuss their behaviour, emotions, and 
ideas with regard to themselves and possible life problems or events40; gender dysphoric individuals 
can experience discomfort with their gender incongruence as a result of internalizing society’s 
normative gender expectations, discrimination, and prejudice66. Finally, psychological interventions 
are also important in the management of posthormonal and surgical outcomes, in order to promote 
the patient’s sense of control and psychological integration of gender role and identity67. Thus, 
psychological support is essential in the assessment, formulation and clinical management of gender 
dysphoria, owing to the complexity and specific needs of gender dysphoric individuals at different 
ages. A variety of psychotherapeutic and psychosocial interventions for gender dysphoria in 
children are well established, including individual insight-oriented psychoanalytic or 
psychodynamic psychotherapy, protocol-driven psychotherapy such as behaviour modification, 
parent and peer relations-focused therapy, and parent and child therapeutic groups, along with 
educational approaches39.  
 
[H2] Physical interventions  
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Physical interventions for gender dysphoria fall into two main categories or stages: cross-sex 
hormonal therapy and gender-reassignment procedures. Hormonal treatment involves the 
administration of cross-sex hormones and is intended to induce the sexual characteristics of the 
desired gender. Hormone therapy is considered a partially reversible intervention64, 65 and, 
according to the Dutch protocol, it should be offered when gender dysphoric adolescents are 16 
years old55, 60. This intervention is considered sufficiently safe and has the ability to enhance the 
individual’s mental as well as physical health57, 59. 
The final stage of gender transitioning is the contemplation of surgical interventions, which 
are considered irreversible procedures. Protocol differences exist across countries and centres, but 
surgery is never carried out on patients <18 years of age, in line with the WPATH Standards of 
Care 3. Both hormonal and surgical intervention options are discussed with patients in detail, and 
during the decision-making process some may choose to undergo only hormonal treatment. 
The use of gender reassignment in adults was pioneered in the 1920s, but no corresponding 
procedure for gender dysphoric children and adolescents was available until the late 1990s. Since 
then, puberty suppression has become increasingly accepted as an early intervention in young 
individuals with clear signs of gender dysphoria64, 65.  
 
[H3] Suppressing puberty 
Suppression of puberty involves the use of GnRHa to halt the progression of puberty by 
blocking the activity of the GnRH receptor at the pituitary level, which results in decreased 
gonadotropin release. As a consequence, the reduced gonadal stimulation leads to a decrease in the 
expression of sex steroids, preventing the development of sexual characteristics or causing them to 
regress to a certain extent, if the individual has already gone through some phases of pubertal 
development (Figure 1). Puberty suppression is considered a fully reversible procedure64, 65 and has 
been proven to be sufficiently safe68. Suppression of puberty in children with gender dysphoria has 
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the fundamental benefit for children of giving them time to reflect on their gender identity, obtain 
real-life experience living as the non-natal gender in dress and behaviour, and determine whether or 
not they desire the full transition46. In our opinion, as the development of a body contrary to the 
experienced gender has been associated with several psychosocial distress parameters, puberty 
suppression can be considered a preventative treatment. The procedure has consistently been linked 
to an improved transition into the desired gender role, including in terms of physical appearance, 
and a more satisfactory outcome, even in the long-term40-42. Nevertheless, the importance of 
continuing to facilitate and support further research on the effects of GnRHa cannot be 
overemphasized.  
 
[H1]Conclusions 
In order to better understand the implications of GnRHa for the psychological and physical 
wellbeing of individuals with childhood onset gender dysphoria in the long-term, further studies are 
needed to directly compare adolescents who underwent an early intervention protocol including 
puberty suppression and adolescents who did not. To date, the absence of robust data in support or 
against the use of GnRHa in the clinical management of childhood onset gender dysphoria has lead 
to inconsistencies between the approaches recommended by health care professionals across 
different centres. The paucity of published research on the effects of GnRHa on health-related 
outcome measures calls for studies which might help to advance the evidence-based debate on risks 
and benefits of puberty suppression. However, careful review of the available data does enable the 
definition of a number of safety criteria for its use (Box 4). Despite a limited number of studies, the 
existing literature supports puberty suppression as an early, sufficiently safe, and preventive 
treatment for gender dysphoria in childhood and adolescence. 
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Key points 
 
Puberty suppression by gonadotropin-releasing hormone analogues is prescribed to relieve 
the distress associated with pubertal development in adolescents with gender dysphoria and thereby 
to provide space for further exploration. 
Treating prepubertal individuals with gender dysphoria is still particularly controversial due 
to their more unstable pattern of gender variance compared to gender dysphoria adolescents and 
adults.  
The absence of robust data in support or against the use of puberty suppression in childhood 
onset gender dysphoria has lead to inconsistencies between health care pathways across different 
centres. 
 The paucity of evidence of the effect of puberty suppression on health-related outcome 
measures calls for studies which might help to advance the evidence-based debate on risks and 
benefits of it. 
 Despite a limited number of studies, the existing literature supports puberty suppression as 
an early, sufficiently safe, and preventive treatment for gender dysphoria in childhood and 
adolescence. 
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 Box 1 | DSM-5 diagnostic criteria for gender dysphoria in adolescents and adults (302.85/F64.1) 
A. A marked incongruence between one’s experience/expressed gender and assigned gender, of at 
least 6 months’ duration, as manifested by at least two of the following: 
1. A marked incongruence between one’s experience/expressed gender and primary and/or 
secondary sex characteristics (or in young adolescents, the anticipated secondary sex 
characteristics). 
2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of 
a marked incongruence with one’s experience/expressed gender (or in young adolescents, the desire 
to prevent the development of the anticipated secondary sex characteristics). 
3. A strong desire for the primary and/or secondary sex characteristics of the other gender. 
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4. A strong desire to be of the other gender (or some alternative gender different from one’s 
assigned gender). 
5. A strong desire to be treated as the other gender (or some alternative gender different 
from one’s assigned gender). 
6. A strong conviction that one has the typical feelings and reactions of the other gender (or 
some alternative gender different from one’s assigned gender). 
B. The condition is associated with clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
Specify if:  
With a disorder of sex development (e.g. a congenital adrenogenital disorder such as 
congenital adrenal hyperplasia or androgen insensitivity syndrome). 
Coding code: Code the disorder of sex development as well as gender dysphoria. 
Specify if:  
 Posttransition: The individual has transitioned to full-time living in the desired gender (with 
or without legalization of gender change) and has undergone (or is preparing to have) at least one 
cross-sex medical procedure or treatment regimen-namely, regular cross-sex hormone treatment or 
gender reassignment surgery confirming the desired gender (e.g. penectomy, vaginoplasty in a natal 
male; mastectomy or phalloplasty in a natal female).    
  
Box 2 | DSM-5 diagnostic criteria for gender dysphoria in children (302.6/F64.2) 
A. A marked incongruence between one’s experienced/expressed gender and assigned gender, of at 
least 6 months’ duration, as manifested by at least six of the following (one of which must be 
Criterion A1): 
1. A strong desire to be of the other gender or an insistence that one is the other gender (or 
some alternative gender different from one’s assigned gender). 
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2. In boys (assigned gender), a strong preference for cross-dressing or simulating female 
attire; or in girls (assigned gender), a strong preference for wearing only typical masculine clothing 
and a strong resistance to the wearing of typical feminine clothing. 
3. A strong preference for cross-gender roles in make-believe play or fantasy play. 
4. A strong preference for the toys, games, or activities stereotypically used or engaged in by 
the other gender. 
5. A strong preference for playmates of the other gender. 
6. In boys (assigned gender), a strong rejection of typically masculine toys, games, and 
activities and a strong avoidance of rough-and-tumble play; or in girls (assigned gender), a strong 
rejection of typically feminine toys, games, and activities. 
7. A strong dislike of one’s sexual anatomy. 
8. A strong desire for the primary and/or secondary sex characteristics that match one’s 
experienced gender. 
B. The condition is associated with clinically significant distress or impairment in social, school, or 
other important areas of functioning. 
Specify if: 
 With a disorder of sex development (e.g., a congenital adrenogenital disorder such as 255.2 
[E25.0] congenital adrenal hyperplasia or 259.50 [E34.50] androgen insensitivity syndrome). 
 
Box 3 | Tanner stages 
Pubic hair (both male and female) 
Tanner 1: no pubic hair at all (typically age 10 and under) 
Tanner 2: small amount of long, downy hair with slight pigmentation at the base of the penis and 
scrotum (males) or on the labia majora (females) (age 10–11)  
Tanner 3: hair becomes more coarse and curly, and begins to extend laterally (age 12–14) 
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Tanner 4: adult-like hair quality, extending across pubis but sparing medial thighs (age 13–15) 
Tanner 5: hair extends to medial surface of the thighs (age 16+) 
Genitals (male) 
Tanner 1: prepubertal (testicular volume less than 1.5 ml; small penis of 3 cm or less) 
Tanner 2: testicular volume between 1.6 and 6 ml; skin on scrotum thins, reddens and enlarges; 
penis length unchanged 
Tanner 3: testicular volume between 6 and 12 ml; scrotum enlarges further; penis begins to lengthen 
to about 6 cm 
Tanner 4: testicular volume between 12 and 20 ml; scrotum enlarges further and darkens; penis 
increases in length to 10 cm and circumference  
Tanner 5: testicular volume greater than 20 ml; adult scrotum and penis of 15 cm in length 
Breasts (female) 
Tanner 1: no glandular tissue; areola follows the skin contours of the chest (prepubertal) 
Tanner 2: breast bud forms, with small area of surrounding glandular tissue; areola begins to widen 
Tanner 3: breast begins to become more elevated, and extends beyond the borders of the areola, 
which continues to widen but remains in contour with surrounding breast  
Tanner 4: increased breast size and elevation; areola and papilla form a secondary mound projecting 
from the contour of the surrounding breast  
Tanner 5: breast reaches final adult size; areola returns to contour of the surrounding breast, with a 
projecting central papilla 
 
Box 4 | Safety criteria for puberty suppression  
1. Puberty suppression cannot be provided until Tanner stage 2 or 3 is reached 
 a. age ≥ 12 years, safely above the gender constancy achievement 
 b. sufficient experience of one’s one natal gender 
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2. Puberty suppression should be offered after extensive evaluation of the condition, as possible 
associated psychosocial risk factors and family issues could affect the decision to start the treatment 
 a. The condition must exhibit clear early onset; persistence and/or increase upon entering 
 puberty and high gender-dysphoria-related distress levels are likely to predict a  positive 
outcome of puberty suppression 
 b. In the presence of psychiatric comorbidities and/or not full understanding of the child’s 
 associated difficulties, the possibility of delaying puberty suppression should be considered 
 and the psychological support should become more relevant  
 c. Support from parents or carers is needed and difficulties in the relationship between 
 patients and their parents or carers should be addressed, considering specific forms of 
 psychotherapy 
3. The decision to start puberty suppression is taken only after considering patients’ and their 
carers’ concerns and expectations after being fully informed on treatment options and expected 
outcome 
 a. potential risks and benefits of proceeding or not proceeding with the treatment should be 
discussed with patients and their parents or carers, in light of the still limited research evidence 
 b. psychoeducation, counselling, and informed consent should be provided to patients and 
 their parents or carers, in order to achieve a full understanding and realistic expectations 
 about the treatment effects 
4. An agreed decision between health-care professionals, patients, and family members should be 
pursued 
 a. the health-care providers’ role is to support and facilitate patients and their parents or 
 carers’ decision 
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 b. disagreements between patients and their parents or carers should be fully addressed, in 
 light of the child’s limited ability to make decisions and the need for parents or carers to 
 provide informed consent on their behalf 
 
 Figure 1 | Puberty suppression 
Suppression of puberty involves the use of GnRHa to halt the progression of puberty by 
blocking the activity of the GnRH receptor at the pituitary level, which results in decreased release 
of the gonadotropins LH and FSH. As a consequence, the reduced gonadal stimulation leads to a 
decrease in the release of sex steroids (testosterone from the testes and estrogen from the ovaries). 
Without exposure to the sex steroids, the body does not undergo the changes associated with them 
(the development of secondary sexual characteristics) which occur during the phases of pubertal 
development. 
CNS, central nervous system; GnRHa, gonadotropin-releasing hormone analogues; LH, 
luteinizing hormone; FSH, follicle-stimulating hormone 
 
  
